Position in HLN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$547,876
-$7,528 QoQ
Shares Held
58,722
+5.8% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#186
of 640 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 1%
Shared 0%
None 99%
Common Shares in HLN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Waverly Advisors, LLC holds $3,254,090 across 7 Drug Manufacturers - Specialty & Generic names. HLN ranks #3 (16.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
5,102 | $859,891 | |
| 2 | ZTS |
Zoetis Inc.
|
9,863 | $708,755 | |
| 3 | HLN |
Haleon plc
This page
|
58,722 | $547,876 | |
| 4 | TEVA |
Teva Pharmaceutical Industries Ltd
|
12,814 | $434,138 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
|
727 | $393,910 | |
| 6 | VTRS |
Viatris Inc
|
17,946 | $284,982 | |
| 7 | ORGO |
Organogenesis Holdings Inc.
|
10,098 | $24,538 |
All Filings in HLN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $547,876 | 58,722 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $555,404 | 55,485 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $620,268 | 61,352 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $294,413 | 32,822 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $325,773 | 31,415 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $324,752 | 31,560 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $298,420 | 31,281 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||